Furthermore, during clinical treatment, especially during NAT, abnormal blood index as bile acid or blood biochemical caused by drug therapy (as neoadjuvant chemotherapy, targeted therapy and immune-checkpoint inhibitors) or other reasons, should be paid fully attention by clinicians, which may be related with TILs and furthering tumor immunity, or even prognosis and treatment efficacy. The gene discussed is BRD2; the disease is neoplasm.